Cancer Research The Future of Cancer Research: Science and Patient Impact Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Camp, R. L.
Right arrow Articles by Rimm, D. L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Camp, R. L.
Right arrow Articles by Rimm, D. L.
[Cancer Research 63, 1445-1448, April 1, 2003]
© 2003 American Association for Cancer Research

Advances in Brief

Quantitative Analysis of Breast Cancer Tissue Microarrays Shows That Both High and Normal Levels of HER2 Expression Are Associated with Poor Outcome1

Robert L. Camp2, Marisa Dolled-Filhart, Bonnie L. King and David L. Rimm

Departments of Pathology [R. L. C., D. L. R.], Genetics [M. D-F.], and Therapeutic Radiology [B. L. K.], Yale University, School of Medicine, New Haven, Connecticut 06520

Using a tissue microarray cohort of 300 breast cancers and 84 samples of normal breast epithelium, we analyzed HER2/neu expression and compared traditional clinical (manual) scoring with a recently developed system for the quantitative measurement of immunohistochemical stains (AQUA). As expected, both methods identified a population (10–15%) of high-HER2-expressing tumors with poor 30-year disease-related survival. Using AQUA analysis, we found that normal epithelium expresses a low but detectable level of HER2 and that 17.5% of tumors exhibit similar low-level HER2 expression. This low group was not definable by manual scoring. Surprisingly, HER2-normal tumors were as aggressive as HER2-overexpressing tumors. Our studies suggest that in situ quantitative measurement of HER2 stratifies breast tumors into three expression levels: normal, intermediate, and high, where both normal and high levels are associated with a worse outcome.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
Y. Nadler, R. L. Camp, C. Schwartz, D. L. Rimm, H. M. Kluger, and Y. Kluger
Expression of Aurora A (but Not Aurora B) Is Predictive of Survival in Breast Cancer
Clin. Cancer Res., July 15, 2008; 14(14): 4455 - 4462.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
W. Huang, Y. Zhang, S. Varambally, A. M. Chinnaiyan, M. Banerjee, S. D. Merajver, and C. G. Kleer
Inhibition of CCN6 (Wnt-1-Induced Signaling Protein 3) Down-Regulates E-Cadherin in the Breast Epithelium through Induction of Snail and ZEB1
Am. J. Pathol., April 1, 2008; 172(4): 893 - 904.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. B. Moeder, J. M. Giltnane, M. Harigopal, A. Molinaro, A. Robinson, K. Gelmon, D. Huntsman, R. L. Camp, and D. L. Rimm
Quantitative Justification of the Change From 10% to 30% for Human Epidermal Growth Factor Receptor 2 Scoring in the American Society of Clinical Oncology/College of American Pathologists Guidelines: Tumor Heterogeneity in Breast Cancer and Its Implications for Tissue Microarray Based Assessment of Outcome
J. Clin. Oncol., December 1, 2007; 25(34): 5418 - 5425.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
S. Rauser, R. Weis, H. Braselmann, M. Feith, H. J. Stein, R. Langer, P. Hutzler, M. Hausmann, S. Lassmann, J. R. Siewert, et al.
Significance of HER2 Low-Level Copy Gain in Barrett's Cancer: Implications for Fluorescence In situ Hybridization Testing in Tissues
Clin. Cancer Res., September 1, 2007; 13(17): 5115 - 5123.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. M. Giltnane, L. Ryden, M. Cregger, P.-O. Bendahl, K. Jirstrom, and D. L. Rimm
Quantitative Measurement of Epidermal Growth Factor Receptor Is a Negative Predictive Factor for Tamoxifen Response in Hormone Receptor Positive Premenopausal Breast Cancer
J. Clin. Oncol., July 20, 2007; 25(21): 3007 - 3014.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. L. Rimm, J. M. Giltnane, C. Moeder, M. Harigopal, G. G. Chung, R. L. Camp, and B. Burtness
Bimodal Population or Pathologist Artifact?
J. Clin. Oncol., June 10, 2007; 25(17): 2487 - 2488.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
E. Pick, Y. Kluger, J. M. Giltnane, C. Moeder, R. L. Camp, D. L. Rimm, and H. M. Kluger
High HSP90 Expression Is Associated with Decreased Survival in Breast Cancer
Cancer Res., April 1, 2007; 67(7): 2932 - 2937.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Dolled-Filhart, L. Ryden, M. Cregger, K. Jirstrom, M. Harigopal, R. L. Camp, and D. L. Rimm
Classification of breast cancer using genetic algorithms and tissue microarrays.
Clin. Cancer Res., November 1, 2006; 12(21): 6459 - 6468.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
F. Bertucci, D. Birnbaum, and A. Goncalves
Proteomics of Breast Cancer: Principles and Potential Clinical Applications
Mol. Cell. Proteomics, October 1, 2006; 5(10): 1772 - 1786.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
Y. Su, M. J. Shrubsole, R. M. Ness, Q. Cai, N. Kataoka, K. Washington, and W. Zheng
Immunohistochemical Expressions of Ki-67, Cyclin D1, {beta}-Catenin, Cyclooxygenase-2, and Epidermal Growth Factor Receptor in Human Colorectal Adenoma: A Validation Study of Tissue Microarrays.
Cancer Epidemiol. Biomarkers Prev., September 1, 2006; 15(9): 1719 - 1726.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. Dolled-Filhart, A. McCabe, J. Giltnane, M. Cregger, R. L. Camp, and D. L. Rimm
Quantitative In situ Analysis of {beta}-Catenin Expression in Breast Cancer Shows Decreased Expression Is Associated with Poor Outcome.
Cancer Res., May 15, 2006; 66(10): 5487 - 5494.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
M. Kidd, I. M. Modlin, S. M. Mane, R. L. Camp, G. Eick, and I. Latich
The Role of Genetic Markers--NAP1L1, MAGE-D2, and MTA1--in Defining Small-Intestinal Carcinoid Neoplasia
Ann. Surg. Oncol., February 1, 2006; 13(2): 253 - 262.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
D. E. Henson
Back to the Drawing Board on Immunohistochemistry and Predictive Factors
J Natl Cancer Inst, December 21, 2005; 97(24): 1796 - 1797.
[Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
A. McCabe, M. Dolled-Filhart, R. L. Camp, and D. L. Rimm
Automated Quantitative Analysis (AQUA) of In Situ Protein Expression, Antibody Concentration, and Prognosis
J Natl Cancer Inst, December 21, 2005; 97(24): 1808 - 1815.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
R. C. Bast Jr., H. Lilja, N. Urban, D. L. Rimm, H. Fritsche, J. Gray, R. Veltri, G. Klee, A. Allen, N. Kim, et al.
Translational Crossroads for Biomarkers
Clin. Cancer Res., September 1, 2005; 11(17): 6103 - 6108.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. Psyrri, Z. Yu, P. M. Weinberger, C. Sasaki, B. Haffty, R. Camp, D. Rimm, and B. A. Burtness
Quantitative Determination of Nuclear and Cytoplasmic Epidermal Growth Factor Receptor Expression in Oropharyngeal Squamous Cell Cancer by Using Automated Quantitative Analysis
Clin. Cancer Res., August 15, 2005; 11(16): 5856 - 5862.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. M. McCarthy, M. Sznol, K. A. DiVito, R. L. Camp, D. L. Rimm, and H. M. Kluger
Evaluating the Expression and Prognostic Value of TRAIL-R1 and TRAIL-R2 in Breast Cancer
Clin. Cancer Res., July 15, 2005; 11(14): 5188 - 5194.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. H. Kim, V. Bossuyt, T. Ponn, D. Lannin, and B. G. Haffty
Cyclooxygenase-2 Expression in Postmastectomy Chest Wall Relapse
Clin. Cancer Res., July 15, 2005; 11(14): 5199 - 5205.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
H. M. Kluger, D. Chelouche Lev, Y. Kluger, M. M. McCarthy, G. Kiriakova, R. L. Camp, D. L. Rimm, and J. E. Price
Using a Xenograft Model of Human Breast Cancer Metastasis to Find Genes Associated with Clinically Aggressive Disease
Cancer Res., July 1, 2005; 65(13): 5578 - 5587.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. Harigopal, A. J. Berger, R. L. Camp, D. L. Rimm, and H. M. Kluger
Automated Quantitative Analysis of E-Cadherin Expression in Lymph Node Metastases Is Predictive of Survival in Invasive Ductal Breast Cancer
Clin. Cancer Res., June 1, 2005; 11(11): 4083 - 4089.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Al-Kuraya, P. Schraml, J. Torhorst, C. Tapia, B. Zaharieva, H. Novotny, H. Spichtin, R. Maurer, M. Mirlacher, O. Kochli, et al.
Prognostic Relevance of Gene Amplifications and Coamplifications in Breast Cancer
Cancer Res., December 1, 2004; 64(23): 8534 - 8540.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. J. Berger, R. L. Camp, K. A. DiVito, H. M. Kluger, R. Halaban, and D. L. Rimm
Automated Quantitative Analysis of HDM2 Expression in Malignant Melanoma Shows Association with Early-Stage Disease and Improved Outcome
Cancer Res., December 1, 2004; 64(23): 8767 - 8772.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. A. DiVito, A. J. Berger, R. L. Camp, M. Dolled-Filhart, D. L. Rimm, and H. M. Kluger
Automated Quantitative Analysis of Tissue Microarrays Reveals an Association between High Bcl-2 Expression and Improved Outcome in Melanoma
Cancer Res., December 1, 2004; 64(23): 8773 - 8777.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. ProteomicsHome page
J. S. Ross, J. A. Fletcher, K. J. Bloom, G. P. Linette, J. Stec, W. F. Symmans, L. Pusztai, and G. N. Hortobagyi
Targeted Therapy in Breast Cancer: The HER-2/neu Gene and Protein
Mol. Cell. Proteomics, April 1, 2004; 3(4): 379 - 398.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. A. Rubin, M. P. Zerkowski, R. L. Camp, R. Kuefer, M. D. Hofer, A. M. Chinnaiyan, and D. L. Rimm
Quantitative Determination of Expression of the Prostate Cancer Protein {alpha}-Methylacyl-CoA Racemase Using Automated Quantitative Analysis (AQUA): A Novel Paradigm for Automated and Continuous Biomarker Measurements
Am. J. Pathol., March 1, 2004; 164(3): 831 - 840.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. M. Kluger, M. Dolled-Filhart, S. Rodov, B. M. Kacinski, R. L. Camp, and D. L. Rimm
Macrophage Colony-Stimulating Factor-1 Receptor Expression Is Associated with Poor Outcome in Breast Cancer by Large Cohort Tissue Microarray Analysis
Clin. Cancer Res., January 1, 2004; 10(1): 173 - 177.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.